Novartis scales down sales force

December 2007
Pharmaceutical Representative;Dec2007, Vol. 37 Issue 12, p10
The article reports on the move of Novartis AG to reduce its U.S. pharmaceuticals organization. The plan was initiated following the suspension of Zelnorm in March 2007, as well as the rise of generic competition for its Lotrel, Lamisil, Famvir brands. A total of 1,260 positions will be eliminated, including 240 from the headquarters in East Hanover, New Jersey, 510 Novartis representatives and 510 third-party representatives. According to the firm, the cut saves about $230 million in 2008.


Related Articles

  • SYSTEMS BIOLOGY'S Awkward Adolescence. Russell, John // Bio-IT World;Sep2007, Vol. 6 Issue 7, p20 

    The article ponders on the role of systems biology (SB) in the pharmaceutical industry and biotechnology. Novartis and GlaxoSmithKline, which are considered the early advocates of SB, have disbanded or deemphasized internal SB departments. Observers think that their action is simply...

  • Do's and Don'ts of Downsizing. Grant, Susan; Cherkis, Carol // Pharmaceutical Executive;May2003, Vol. 23 Issue 5, p102 

    Reports on the importance of business planning in handling corporate downsizing among pharmaceutical companies in the U.S. Advantage of positive industrial relations; Preparation for employee retrenchment; Executive training to conduct layoffs. INSETS: Step by Step;Breaking the News.

  • Novartis -- Italian style.  // European Pharmaceutical Executive;Oct2007, p13 

    The article reports that Daniel Vasella, chairman of Novartis AG, has announced that the company is set to invest in research and innovation in Italy. The company is planning to split the €600 million investment between its existing vaccine research center in Siena and in the creation of a...

  • First-quarter biotech job picture. Francisco, Michael // Nature Biotechnology;May2011, Vol. 29 Issue 5, p460 

    The article presents an overview of the biotechnology and pharmaceutical jobs sector for the first quarter of 2011. Data indicate an increase in the number of companies that have advertised more jobs as compared to the fourth quarter of the previous year. Senior scientist positions in China have...

  • Novartis slashes sales force as delays, setbacks sink in. S. M. // Medical Marketing & Media;Nov2007, Vol. 42 Issue 11, p9 

    The article provides an overview of the sales performance of Novartis AG in the U.S. 1,260 jobs will be cut from the U.S. sales and marketing department. In addition, Joe Jimenez has been named to head the prescription drug unit. Jimenez will oversee the cuts, which are meant to save the company...

  • Novartis.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p63 

    Features the Novartis, a pharmaceutical manufacturer. Focus of its research and development efforts; Estimated spendings on worldwide research and development activities for the year 2000; Trading on the New York Stock Exchange; Top-selling products; Pharmaceutical products that have received...

  • Novartis primes pipeline.  // Medical Marketing & Media;May2003, Vol. 38 Issue 5, p14 

    Reports on the plans of pharmaceutical firm Novartis AG. Novartis' plan to buy a stake at Idenix Pharmaceuticals Inc.; Development of drugs for the treatment of hepatitis B; Licensing agreement of Novartis with Regeneron Pharmaceuticals Inc.

  • Novartis to cut, transfer up to 4,000 pharma jobs to India.  // BioSpectrum;Mar2014, Vol. 12 Issue 3, p12 

    The article discusses the move of Novartis AG, a Swiss pharmaceutical company, to consider reducing or transferring up to 4,000 jobs to India.

  • Palatin to Cut Jobs. Gaudio, Thomas // njbiz;5/19/2008, Vol. 21 Issue 21, p2 

    The article reports on a plan by Cranbury, New Jersey-based biopharmaceutical firm Palatin Technologies Inc. to reduce its work force by 30 percent, as of May 2008. Palatin aims to align its human resources with its new strategic objectives. The company has changed the focus of developing one of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics